San Diego, CA 10/5/15—Illumina has announced third quarter sales of $550 million, 3% lower than expected, due to softer demand for desktop sequencers, and weaker sales in Europe and Asia Pacific. As a result, the company revised its full-year sales guidance downward from 20% growth to 18% growth, or a 21% increase in constant currency. Third quarter sales increased 14%, or 18% in constant currency. On a conference call discussing the announcement, Illumina CEO Jay Flatley stated, “We do expect non-GAAP EPS to come in below the current consensus expectations consistent with a 3% revenue shortfall.” Although sales of NextSeq systems were below expectations, third quarter shipments of sequencing consumables increased 36%, and HiSeq X revenue exceeded expectations. European sales grew 6%, as deals and shipments slipped into the following quarter. Asia Pacific revenue was flat, primarily due to Japan’s funding environment. However, Americas revenue rose 22%. In addition, during the quarter, the company completed its transition to a new enterprise transaction system, resulting in a $5 million revenue slippage into the next quarter related to manufacturing issues. “Importantly, the factors contributing to the Q3 shortfall do not dampen our long-term expectations for revenue growth, which remain at 15%–20% through 2016,” said Mr. Flatley.